Friday, 6 November 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Business Update

Zydus Lifesciences Business Update

Zydus Lifesciences' subsidiary presented Phase 2b trial data for investigational saroglitazar in MASH at AASLD 2026. The drug showed higher steatohepatitis resolution than placebo, but its safety and effectiveness for this use are not yet established.

Source

BSE filing, NSE: ZYDUSLIFE. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Zydus Lifesciences Ltd: key numbers

Share price
₹1,197.90
Market cap
₹1,20,537 Cr
Revenue (annual)
₹27,148 Cr
Net profit (annual)
₹5,040 Cr
P/E (TTM)
28.8×Sector 42.0×
Promoter holding
75.01%+0.00% QoQ
FII holding
7.05%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Zydus Lifesciences Ltd

All →

Other business update announcements

All →